Pharming Group Net Profit Margin 2013-2024 | PHGUF

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Pharming Group net profit margin from 2013 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Pharming Group net profit margin from 2013 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$141.6B
Bristol Myers Squibb (BMY)	$116.3B
Gilead Sciences (GILD)	$115.4B
Vertex Pharmaceuticals (VRTX)	$102.3B
CSL (CSLLY)	$83.8B
Regeneron Pharmaceuticals (REGN)	$77.1B
GSK (GSK)	$69.6B
Argenex SE (ARGX)	$37.7B
Alnylam Pharmaceuticals (ALNY)	$31.7B
BioNTech SE (BNTX)	$27.1B
Illumina (ILMN)	$21.6B
Biogen (BIIB)	$21.3B
BeiGene (BGNE)	$17.2B
Moderna (MRNA)	$15.2B
Genmab (GMAB)	$13.4B
Incyte (INCY)	$13.3B
Insmed (INSM)	$12.6B
BioMarin Pharmaceutical (BMRN)	$12.5B
Bio-Techne Corp (TECH)	$11.6B
Sarepta Therapeutics (SRPT)	$11.4B
Exact Sciences (EXAS)	$11B
Vaxcyte (PCVX)	$10.8B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$10.2B
Exelixis (EXEL)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.8B
Roivant Sciences (ROIV)	$8.4B
Ascendis Pharma (ASND)	$8.3B
Repligen (RGEN)	$8.1B